U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Fixed-Dose Combinations of Drugs versus Single-Drug Formulations for Treating Pulmonary Tuberculosis

About this resource:

Systematic review

Source: The Cochrane Collaborative

Last Reviewed: May 2016

Workgroups: Global Health Workgroup, Immunization and Infectious Diseases Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that fixed-dose combinations (FDCs) of anti-tuberculosis medicines may have similar effects as single‐drug formulations for treating people with newly diagnosed pulmonary tuberculosis. The treatment for pulmonary tuberculosis in new patients includes 4 medicines taken by mouth for 6 months, sometimes as FDCs that are combined in 1 tablet and sometimes taken separately as single-drug formulations. Researchers found little to no difference in outcomes for people taking FDCs compared with those taking single-drug formulations.

Read more about this resource

Objectives related to this resource (1)

Reduce tuberculosis cases — IID‑17
Improving

Suggested Citation

1.

Gallardo, C.R., Rigau Comas, D., Valderrama Rodríguez, A., Roqué i Figuls, M., Parker, L.A., Caylà, J. & Bonfill Cosp, X. Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews, 2016 (5). DOI: 10.1002/14651858.CD009913.pub2